A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)

Sequential administration of the association of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel could be better tolerated than the association of an anthracycline and paclitaxel while having a similar antitumour effect. 69 patients with advanced breast cancer previously untreate...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccardi, A, Pugliese, P, Danova, M, Brugnatelli, S, Grasso, D, Giordano, M, Bernardo, G, Giardina, G, Fava, S, Montanari, G, Pedrotti, C, Trotti, G, Rinaldi, E, Poli, M A, Tinelli, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364040/
https://www.ncbi.nlm.nih.gov/pubmed/11461067
http://dx.doi.org/10.1054/bjoc.2001.1897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364040/
https://www.ncbi.nlm.nih.gov/pubmed/11461067
http://dx.doi.org/10.1054/bjoc.2001.1897

Ejemplares similares